Insight into conformational change for 14-3-3σ protein by molecular dynamics simulation.

Revealing the binding modes and the unbinding of 14-3-3σ proteins and inhibitors by computational methods. Sci Rep (2015) 0.80

Conformational stability of PCID2 upon DSS1 binding with molecular dynamics simulation. J Mol Model (2015) 0.75

Chimeric 14-3-3 proteins for unraveling interactions with intrinsically disordered partners. Sci Rep (2017) 0.75

Exploring the binding pathways of the 14-3-3ζ protein: Structural and free-energy profiles revealed by Hamiltonian replica exchange molecular dynamics with distancefield distance restraints. PLoS One (2017) 0.75

The Amber biomolecular simulation programs. J Comput Chem (2005) 28.84

A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem (2003) 15.88

The structural basis for 14-3-3:phosphopeptide binding specificity. Cell (1997) 10.87

Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins (2004) 9.15

14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol (2000) 6.94

LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model (2011) 6.49

14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature (1999) 5.44

Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding. Mol Cell (1999) 4.02

14-3-3 proteins: a historic overview. Semin Cancer Biol (2006) 3.91

Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J Mol Biol (2003) 3.89

14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochem J (2004) 3.60

A series of PDB related databases for everyday needs. Nucleic Acids Res (2010) 3.60

Crystal structure of the zeta isoform of the 14-3-3 protein. Nature (1995) 2.98

The eukaryotic host factor that activates exoenzyme S of Pseudomonas aeruginosa is a member of the 14-3-3 protein family. Proc Natl Acad Sci U S A (1993) 2.50

Structural determinants of 14-3-3 binding specificities and regulation of subcellular localization of 14-3-3-ligand complexes: a comparison of the X-ray crystal structures of all human 14-3-3 isoforms. Semin Cancer Biol (2006) 2.42

Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature (2002) 2.32

A structural basis for 14-3-3sigma functional specificity. J Biol Chem (2005) 2.20

The effect of fulvic acid on pre- and postaggregation state of Aβ(17-42): molecular dynamics simulation studies. Biochim Biophys Acta (2012) 2.01

Structural basis for protein-protein interactions in the 14-3-3 protein family. Proc Natl Acad Sci U S A (2006) 1.95

14-3-3 proteins in cell cycle regulation. Semin Cancer Biol (2006) 1.83

AMBER force-field parameters for phosphorylated amino acids in different protonation states: phosphoserine, phosphothreonine, phosphotyrosine, and phosphohistidine. J Mol Model (2005) 1.69

Structural basis of 14-3-3 protein functions. Semin Cell Dev Biol (2011) 1.60

Proteomic identification of 14-3-3zeta as a mitogen-activated protein kinase-activated protein kinase 2 substrate: role in dimer formation and ligand binding. Mol Cell Biol (2003) 1.53

C-terminal binding: an expanded repertoire and function of 14-3-3 proteins. FEBS Lett (2006) 1.29

14-3-3 is phosphorylated by casein kinase I on residue 233. Phosphorylation at this site in vivo regulates Raf/14-3-3 interaction. J Biol Chem (1997) 1.22

The folding pathway of spectrin R17 from experiment and simulation: using experimentally validated MD simulations to characterize States hinted at by experiment. J Mol Biol (2006) 1.21

Binding induced folding in p53-MDM2 complex. J Am Chem Soc (2007) 1.15

The crystal structure of the non-liganded 14-3-3sigma protein: insights into determinants of isoform specific ligand binding and dimerization. Cell Res (2005) 1.13

Structure of a 14-3-3σ-YAP phosphopeptide complex at 1.15 A resolution. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 1.04

The role of protein disorder in the 14-3-3 interaction network. Mol Biosyst (2011) 1.01

Stabilization and inhibition of protein-protein interactions: the 14-3-3 case study. ACS Chem Biol (2012) 0.90

14-3-3 proteins are required for the inhibition of Ras by exoenzyme S. Biochem J (2000) 0.88

Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations. Int J Mol Sci (2012) 0.88

Critical residue that promotes protein dimerization: a story of partially exposed Phe25 in 14-3-3σ. J Chem Inf Model (2011) 0.84

Insights into scFv:drug binding using the molecular dynamics simulation and free energy calculation. J Mol Model (2010) 0.81

Understanding the molecular mechanism of enzyme dynamics of ribonuclease A through protonation/deprotonation of HIS48. J Am Chem Soc (2011) 0.80

Determinants of 14-3-3σ protein dimerization and function in drug and radiation resistance. J Biol Chem (2013) 0.80

Insights into the mechanisms of the selectivity filter of Escherichia coli aquaporin Z. J Mol Model (2012) 0.77